 JUPITER, Fla., Sept. 10, 2021 GLOBE NEWSWIRE -- Dyadic International, Inc. Dyadic, we, us, our, or the Company NASDAQ:DYAI, a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics at flexible commercial scales, today announced that the Companys management will be attending and presenting at the following upcoming virtual investor event: 